Artificial Intelligence for New Drug Design

A Technology Platform for Deep-Learning-Based de novo Drug Design
Digital tools are a key to shortening the development of active pharmaceutical ingredients and thus market-ready drugs and therapies. Big data and artificial intelligence (AI) can significantly accelerate many processes and make them more efficient. The Paris, Francebased start-up Iktos is developing a proprietary AI technology for ligand and structure-based de novo drug design, focusing on multi parametric optimization (MPO). Yann Gaston-Mathé, co-founder and CEO of Iktos, explains the company’s technologies and provides an outlook on the further development of the company.